These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38820269)

  • 21. Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.
    Med Lett Drugs Ther; 2020 Jan; 62(1589):5-7. PubMed ID: 31999662
    [No Abstract]   [Full Text] [Related]  

  • 22. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
    Hoy SM
    Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
    Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
    Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two
    Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA
    Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849
    [No Abstract]   [Full Text] [Related]  

  • 25. Challenges in the treatment of cystic fibrosis in the era of CFTR modulatorsAuthors' replyUse of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele a systematic review and meta-analysisDiscontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY) results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsAssessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.
    Schmidt CJ; Moura LS; Dalcin PTR; Ziegler B
    J Bras Pneumol; 2024 May; 50(2):e20240107. PubMed ID: 38808835
    [No Abstract]   [Full Text] [Related]  

  • 26. Lung clearance index (LCI
    Urquhart DS; Dowle H; Moffat K; Forster J; Cunningham S; Macleod KA
    Pediatr Pulmonol; 2024 May; 59(5):1449-1453. PubMed ID: 38415920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
    Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
    Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence and evolution of
    Armbruster CR; Hilliam YK; Zemke AC; Atteih S; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Lee SE; Cooper VS; Bomberger JM
    mBio; 2024 May; 15(5):e0051924. PubMed ID: 38564694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis.
    Smith M; Ryan KJ; Gutierrez H; Sanchez LHG; Anderson JN; Acosta EP; Benner KW; Guimbellot JS
    J Cyst Fibros; 2022 Jan; 21(1):e8-e10. PubMed ID: 34130909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment.
    Nielsen BU; Olsen MF; Mabuza Mathiesen IH; Pressler T; Ritz C; Katzenstein TL; Olesen HV; Skov M; Jensen-Fangel S; Almdal TP; Faurholt-Jepsen D
    J Cyst Fibros; 2024 Jan; 23(1):103-108. PubMed ID: 37989700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two
    Graeber SY; Renz DM; Stahl M; Pallenberg ST; Sommerburg O; Naehrlich L; Berges J; Dohna M; Ringshausen FC; Doellinger F; Vitzthum C; Röhmel J; Allomba C; Hämmerling S; Barth S; Rückes-Nilges C; Wielpütz MO; Hansen G; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
    Am J Respir Crit Care Med; 2022 Aug; 206(3):311-320. PubMed ID: 35536314
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: A retrospective review.
    Guenther EL; McCoy KS; Eisner M; Bai S; Nemastil CJ; Novak KJ; Johnson T; Stephan EM
    J Cyst Fibros; 2024 Jan; 23(1):32-37. PubMed ID: 37069044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype.
    Carnovale V; Iacotucci P; Terlizzi V; Colangelo C; Medio P; Ferrillo L; De Gregorio F; Francalanci M; Taccetti G; Buonaurio S; d'Ippolito M; Marsicovetere G; D'Andria M; Ferrara N; Salvatore D
    Respir Med; 2021; 189():106646. PubMed ID: 34673344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
    Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
    J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations.
    Munck A; Kerem E; Ellemunter H; Campbell D; Wang LT; Ahluwalia N; Owen CA; Wainwright C
    J Cyst Fibros; 2020 Nov; 19(6):962-968. PubMed ID: 32546431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting weight gain in patients with cystic fibrosis on triple combination modulator.
    Stewart KL; Szczesniak R; Liou TG
    Pediatr Pulmonol; 2024 Jun; 59(6):1724-1730. PubMed ID: 38607242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elexacaftor-tezacaftor-ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis.
    Zemke AC; Hilliam Y; Stapleton AL; Kimple AJ; Goralski JL; Shaffer AD; Pilewski JM; Senior BA; Lee SE; Cooper VS
    Int Forum Allergy Rhinol; 2024 May; 14(5):928-938. PubMed ID: 37837613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
    Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
    Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral lung effect of elexacaftor/tezacaftor/ivacaftor in adult cystic fibrosis.
    Stylemans D; Darquenne C; Schuermans D; Verbanck S; Vanderhelst E
    J Cyst Fibros; 2022 Jan; 21(1):160-163. PubMed ID: 33832855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.